Edaravone: a new hope for deadly amyotrophic lateral sclerosis

Drugs of Today
R BhandariA Kuhad

Abstract

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a fatal motor neuron degenerative disorder leading to paralysis and eventual death. At present, we do not have any specific cure for this deadly disorder. Current drug therapy can only reduce morbidity in ALS patients. In 1995, riluzole was the first drug approved by the U.S. Food and Drug Administration (FDA) for ALS. After a long gap of 22 years, Mitsubishi Tanabe Pharma America got U.S. FDA approval for edaravone (Radicava) in May 2017 for the management of ALS. Edaravone, a novel neuroprotective agent, is indicated to slow down progression of ALS. In 2015, Mitsubishi Tanabe Pharma launched edaravone (Radicut) for the treatment of stroke and ALS in Japan. The U.S. FDA approved edaravone following clinical evidence from three clinical trials conducted in 368 ALS patients in Japan. Edaravone is awaiting approval by the European Medicines Agency (EMA) in Europe. Edaravone (60 mg) is administered by very slow intravenous infusion (60 minutes) in 28-day cycles. It has been shown to slow down the loss of physical function in ALS patients by 33% as compared to placebo. Edaravone is a strong antioxidant that prevents oxidative stress from inducing motor ...Continue Reading

Citations

May 31, 2019·International Journal of Molecular Sciences·Natalia NowickaJoanna Wojtkiewicz
Sep 17, 2019·The Journal of Physiology·Véronique Marchand-PauvertPierre-François Pradat
Mar 4, 2020·Antioxidants & Redox Signaling·Hervé Kovacic
Apr 18, 2020·Therapeutic Hypothermia and Temperature Management·Jayanti SinghSuhrud M Rajguru
Nov 22, 2018·MMWR. Morbidity and Mortality Weekly Report·Paul MehtaKevin Horton
Dec 6, 2018·Neurotoxicity Research·Peter W FrenchGilles J Guillemin
Apr 9, 2019·Stem Cells International·Agnese GugliandoloEmanuela Mazzon
Oct 23, 2020·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Zaynab ShakkourFiras Kobeissy
Nov 26, 2020·Cellular and Molecular Neurobiology·Zhenzhen XuRenshi Xu
Nov 28, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A V AlessenkoA A Ustyugov
Dec 29, 2020·Neuroscience and Biobehavioral Reviews·Regine Sitruk-WareCesar V Borlongan
Nov 17, 2020·Frontiers in Neuroscience·Giovanna MorelloSebastiano Cavallaro
Apr 28, 2020·Redox Biology·Peter J Barnes
Mar 12, 2021·Clinical Pharmacology in Drug Development·Hidetoshi ShimizuKazuoki Kondo
May 7, 2021·Clinical Pharmacology in Drug Development·Hidetoshi ShimizuKazuoki Kondo
Jun 3, 2021·International Journal of Molecular Sciences·Valentina La CognataSebastiano Cavallaro
Oct 13, 2021·Journal of Medicinal Chemistry·Scott E CollibeeBradley P Morgan

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.